<?xml version="1.0" encoding="UTF-8"?>
<p id="Par89">The data highlights the wide range of CMGs for acute, community-acquired CNS infections in use across Europe and variations in quality, clinical case definitions for guiding identification and in initial clinical recommendations. Most CMGs were produced by national or European organisations. Several survey respondents reported using CMGs produced by other countries in or outside of Europe, which may have implications for timely identification of causative pathogens and use of antibiotics, unless they are adapted to regional epidemiology.</p>
